Immunomodulatory effect of immunoglobulins

Clinical and Experimental Rheumatology

Volumn 14, Issue SUPPL. 15, 1996, Pages

  Wolf, H M ^a   Eibl, M M ^a,b,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Department of Immunology ^*  (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Fc mediated functions; immunoglobulins; immunomodulation

Indexed keywords

IMMUNOGLOBULIN;

AUTOIMMUNITY; CONFERENCE PAPER; DRUG THERAPY; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; THERAPY;

ANIMALS; CYTOKINES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECEPTORS, FC; SIALOGLYCOPROTEINS;

EID: 0029739445     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (88)

1. EIBL MM, WEDGWOOD RJ: Intravenous immunoglobulin: a review. Immunodefic Rev 1989; 1 (Suppl): 1-42.
2. SIBER GR, SNYDMAN DR: Use of immune globulins in the prevention and treatment of infections. Curr Clin Top Infect Dis 1992; 12: 208-56.
3. DWYER JM: Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-15.
4. IMBACH P, BARANDUN S, D'APUZZO V, BAUMGARTNER C, HIRT A, MORELL A, ROSSI E, SCHONI M, VEST M, WAGNER HP: High dose intravenous gamma globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-31.
5. BLANCHETTE V, IMBACH P, ANDREW A, et al : Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344: 703-7.
6. BLANCHETTE VS, LUKE B, ANDREW M, SOMMERVILLE-NIELSEN S, BARNARD D, DE VEBER B, GENT M: A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989-95.
7. CLARKSON SB, BUSSEL JB, KIMBERLY RP, VALINSKY JE, NACHMAN RL, UNKELESS JC: Treatment of refractory immune thrombocytopenic purpura with anti-Fc gamma receptor antibody. N Engl J Med 1986; 314: 1236.
8. ROSSI F, DIETRICH G, KAZATCHKINE MD: Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110: 135-49.
9. NEWBURGER JW, TAKAHASHI M, BURNS JC, et al.: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7.
10. NEWBURGER JW, TAKAHASHI M, BEISER AS, et al.: A single infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-9.
11. LEUNG DYM, COTRAN RS, KURT-JONES EZ, BURNS JC, NEWBURGER JW, POBER JS: Endothelial cell activation and increased interleukin 1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989; 2: 1298-302.
12. MEISSNER HC, SCHLIEVERT PM, LEUNG DYM: Mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis, Immunol Rev 1994; 139: 109-23.
13. DALAKAS MC, ILLA I, DAMBROSIA JM, SOUEIDAN SA, STEIN DP, OTERO C, DINSMORE S, MCCORSKY S: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. W Engl J Med 1993; 329: 1993-2000.
14. BASTA M, KIRSCHBOM P, FRANK MM, FRIES LF: Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84: 1974-81.
15. BASTA M, DALAKAS MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35.
16. DALAKAS MC: Polymyositis, dermatomyositis, and inclusion-body myositis.N Engl J Med 1991; 325: 1487-98.
17. VAN DER MECHÉ FGA, SCHMITZ PIM, and the DUTCH GUILLAIN-BARRÉ STUDY GROUP: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9.
18. VAN DOORN PA, BRAND A, STRENGERS PFW, MEULSTEE J, VERMEULEN M: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Neurology 1990; 40: 209-12.
19. RATKO TA, BURNETT DA, FOULKE GE, MATUSZEWSKI KA, SACHER RA, and the UNIVERSITY HOSPITAL CONSORTIUM EXPERT PANEL FOR OFF-LABEL USE OF POLYVALENT INTRAVENOUSLY ADMINISTERED IMMUNOGLOBULIN PREPARATIONS: Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273: 1865-70.
20. KOSKI CL, SANDERS ME, SWOVELAND PT, LAWLEY TJ. SHIN ML, FRANK MM, JOINER KA: Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies. J Clin Invest 1987; 80: 1492-7.
21. ANTONELLI A, SARACINO A, ALBERTI B, CANAPICCHI R, CARTEI F, LEPRI A, LADDAGA M, BASCHIERI L: High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol 1992; 126: 13-23.
22. ANTONELLI A, NAVARRANE A, PALLA R, ALBERTI B, SARACINO A, MESTRE C, ROGER P, AGOSTINI A, BASCHIERI L: Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid 1994; 4: 399-408.
23. DUSE M, TIBERTI S, PLEBANI A, AVANZINI MA, GARDENGHI M, MENEGATI E, MONAFO V, UGAZIO AG: IgG2 deficiency and intractable epilepsy of childhood. Monogr Allergy 1986; 20: 128-134.
24. STERIO M, GEBAUER E, VUCICEVIC G, ZALISEVSKIJ G, FELLE D, KOLAROV N: Intravenöses Immunglobulin bei der Behandlung von malignen Epilepsien bei Kindern. Wr Klin Wochenschr 1990; 102: 230-3.
25. ILLUM N, TAUDORF K, HEILMANN C, SMITH T, WULFF K, MANSA B, PLATZ P: Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990; 21: 87-90.
26. ARIZUMI M, SHIIHARA H, HIBIO S, RYO S, BABA K, OGAWA K, SUZUKI Y, MOMOKI T: High dose gamma-globulin for intractable childhood epilepsy. Lancet 1983; 2: 162-3.
27. ETZIONI A, JAFFE M, POLLACK S, ZELNIK N, BENDERLY A, TAL Y: High dose intravenous gamma-globulin in intractable epilepsy of childhood. Eur J Pediatr 1991; 150: 681-3.
28. BERNATOWSKA-MATUSZKIEWICZ E, PAC M. SKOPCYNSKA H, PUM M, EIBL MM: Clinical efficacy of intravenous immunoglobulin in patients with severe inflammatory chest disease and IgG3 subclass deficiency. Clin Exp Immunol 1991; 85: 193-7.
29. MAZER BD, GELFAND EW: An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991; 87: 976-83.
30. ROUX KH, TANKERSLEY DL: A view of the human idiotypic repertoire. Electron microscopic and immunologie analysis of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990; 144: 1387-95.
31. TANKERSLEY DL, PRESTON MS, FINLAYSON JS: Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988; 25: 41-8.
32. MANNHALTER JW, WOLF HM, GÖTTLICHER J, AHMED R, EIBL MM: Modulation of Fc gamma receptors in the membrane of human monocytes: effect on monocyte functions. Acta Paediatr Hung 1990; 30: 143-54.
33. KIMBERLY RP, SALMON JE, BUSSEL JB, CROW MK, HILGARTNER MW: Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 1984; 132:745-50.
34. SALMON JE, KAPUR S, KIMBERLY RP: Gammaglobulin for intravenous use induces an Fc gamma receptor-specific decrement in phagocytosis by blood monocytes. Clin Immunol Immunopathol 1987; 43: 23-33.
35. SULTAN Y, KAZATCHKINE MD, MAISONNEUVE P, NYDEGGER UE: Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-8.
36. ROSSI F, KAZATCHKINE MD: Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989, 143: 4104-9.
37. MARCHALONIS JJ, KAYAMAZ H, DEDEOGLU F, SCHLUTER SF, YOCUM DE, EDMUNDSON AB: Human autoantibodies reactive with synthetic autoantigens from T-cell receptor ß chain. Proc Natl Acad Sci USA 1992; 89: 3325-9.
38. GORDON JM, COHEN P, FINLAYSON JS: Levels of anti-A and anti-B in commercial immune globulins. Transfusion 1980; 26: 90-2.
39. BROCHIER J, BONNEAU M, ROBERT M, SAMARUT C, RIVELLARD JP, TRAEGER J: Anti-HLA DR allo-antibodies eluted from human placental tissue. Transplant Proc 1979; 11:779-82.
40. QUINTI I, PAPETTI C, PAGANELLI R, D'AMELIO R, NISINI R, DOFFIZI G, AIUTO F: Evaluation of the presence of RF-like activities in immunoglobulin preparations for intravenous use. I. IgG anti-IgE in intravenous Ig. J Clin Lab Immunol 1987; 24: 135-8.
41. VASSILEV T, GELIN C, KAVERI SV, ZILBER M-T, BOUMSELL L, KAZATCHKINE MD: Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIG). Clin Exp Immunol 1993; 92: 369-72.
42. LAM L, WHITSETT CF, MCNICHOLL JM, HODGE TW, HOOPER J: Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342: 678.
43. BLASCZYK R, WESTHOFF U, GROSSE-WILDE H: Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-90.
44. GROSSE-WILDE H, BLASCZYK R, WESTHOFF U: Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 1992; 39: 74-7.
45. SANTOSO S, KIEFEL V, VOLZ H, MUELLER-ECKHARDT C: Quantitation of soluble HLA class I antigen in human albumin and immunoglobulin preparations for intravenous use by solid-phase immunoassay. Vox Sang 1992; 62: 29-33.
46. LEUNG DYM, BURNS JC, NEWBURGER JW, GEHA RS: Reversal of immunoregulatory abnormalities in Kawasaki syndrome by intravenous gamma globulin. J Clin Invest 1987; 79: 468-72.
47. LANG BA, SILVERMAN ED, LAXER RM, LAU AS: Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr 1989; 115: 939-43.
48. NATHAN CF: Secretory products of macrophages. J Clin Invest 1987; 79: 319-26.
49. ANDERSSON J, BJÖRK L, DINARELLO CA, TOWBIN H, ANDERSSON U: Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. Eur J Immunol 1992; 22: 2617-23.
50. DINARELLO CA, WOLFF SM: The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106-13.
51. BEUTLER B, CERAMI A: The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 1989; 7: 625-55.
52. CHEN AR, MCKINNON KP, KOREN HS: Lipopolysaccharide (LPS) stimulates fresh human monocytes to lyse actinomycin D-treated WEHI-164 target cells via increased secretion of a monokine similar to tumor necrosis factor. J Immunol 1985; 135: 3978-87.
53. KORNBLUTH RS, EDGINGTON TS: Tumor necrosis factor production by human monocytes is a regulated event: induction of TNF-α-mediated cellular cytotoxicity by endotoxin. J Immunol 1986; 137: 2585-91.
54. VAN SNICK J: Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-78.
55. KISHIMOTO T: The biology of interleukin-6. Blood 1989; 74: 1-10.
56. BEUTLER B, CERAMI A: Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-85.
57. TRACEY KJ, BEUTLER B, LOWRY SF, MERRYWEATHER J, WOLPE S, MILSARK IW, HARIRI RJ, FAHEY TJ, ZENTELLA A, ALBERT JD, SHIRES GT, CERAMI A: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
58. LEHMANN V, FREUDENBERG MA, GALANOS C: Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med 1987; 165: 657-63.
59. TRACEY KJ, FONG Y, HESSE DG, MANOGUE KR, LEE AT, KUO GC, LOWRY SF, CERAMI A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4.
60. MATHISON JC, WOLFSON E, ULEVITCH RJ: Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1998; 81: 1925-37.
61. BEUTLER B, MILSARK IW, CERAMI A: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-71.
62. GIRARDIN E, GRAU G, DAYER JM, ROUX-LOMBARD P, LAMBERT PH: Tumor necrosis factor and interleukin-1 in serum of children with severe infectious purpura. N Engl J Med 1988; 319: 397-400.
63. CALANDRA T, BAUMGARTNER JD, GRAU GE, WU MM, LAMBERT PH, SCHELLEKENS J, VERHOEF J, GLAUSER MP, and THE SWISS-DUTCH J5 STUDY GROUP: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, alpha-interferon and gamma-interferon in the serum of patients with septic shock. J Infect Dis 1990; 161: 982-7.
64. SHIMOZATO T, IWATA M, TAMURA N: Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun 1990; 58: 1384-90.
65. IWATA M, SHIMOZATO T, TOKIWA H, TSUBURA E: Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits. Infect Immun 1987; 55: 547-54.
66. SHIMOZATO T, IWATA M, KAWADA H, TAMURA N: Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 1991; 72: 497-501.
67. ANDERSSON JP, ANDERSSON UG: Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71: 372-6.
68. KUHNERT P, SCHALCH L, JUNGI TW: Cytokine induction in human mononuclear cells stimulated by IgG-coated culture surfaces and by IgG for infusion. Clin Immunol Immunopathol 1990; 57: 218-32.
69. THE INTRAVENOUS IMMUNOGLOBULIN COLLABORATIVE STUDY GROUP: Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992; 327: 234-40.
70. WOLF HM, FISCHER MB, PÜHRINGER H, SAMSTAG A, VOGEL E, EIBL MM: Human serum IgA down-regulates the release of inflammatory cytokines (TNF-alpha, IL-6) in human monocytes. Blood 1994; 83: 1278-88.
71. MAE N, LIBERATO JD, CHIZZONITE R, SATOH H: Identification of high-affinity anti-IL1α autoantibodies in normal human serum as an interfering substance in a sensitive enzyme-linked immunosorbent assay for IL-1α. Lymphokine Cytokine Res 1991; 10: 61.
72. BENDTZEN K, SVENSON M, JONSSON V, HIPPE E: Autoantibodies to cytokines. Immunol Today 1990; 11: 167.
73. SVENSON M, BAGGE HANSEN M, BENDTZEN K: Distribution and characterization of autoantibodies to interleukin 1α in normal human sera. Scand J Immunol 1990; 29: 489.
74. SVENSON M, HANSEN MB, BENDTZEN K: Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92: 2533.
75. AREND WP: Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167-227.
76. AREND WP, JOSLIN FG, MASSONI RJ: Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 1985; 134: 3868-75.
77. AREND WP, SMITH MF, JANSON RW, JOSLIN FG: IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently. J Immunol 1991; 147: 1530-6.
78. POUTSIAKA DD, CLARK BD, VANNIER E, DINARELLO CA: Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78: 1275-81.
79. AREND WP, LEUNG DYM: IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1994; 139: 71-8.
80. ANDERSSON U, BJÖRK L, SKANSÉN-SAPHIR U, ANDERSSON J: Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139: 21-42.
81. SCHUR PH, CHANG D-M, BAPTISTE P, UHTEG LC, HANSON DC: Human monocytes produce IL-1 and an inhibitor of IL-1 in response to two different signals. Clin Immunol Immunopathol 1990; 57: 45-63.
82. MARSH CB, POPE HA, WEWERS MD: Fey receptor crosslinking down-regulates IL-1 receptor antagonist and induces IL-1β in mononuclear phagocytes stimulated with endotoxin or Staphylococcus aureus. J Immunol 1994; 152:4604-11.
83. FISCHER E, VANZEE KJ, MARANOMA, ROCK CS, KENNEY JS, POUTSIAKA DD, DINARELLO CA, LOWRY SF, MOLDAWER LL: Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992; 79: 2196-200.
84. AREND WP: Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445-51.
85. AREND WP, WELGUS HG, THOMPSON RC, EISENBERG SP: Biological properties of recombinant human monocyte-derived interleukin 1 receptor antangonist. J Clin Invest 1990; 85; 1694-7.
86. DINARELLO CA, THOMPSON RC: Blocking IL-1 : interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12:404-10.
87. TAKEI S, ARORA YK, WALKER SM: Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91: 602-7.
88. SKANSEN-SAPHIR U, ANDERSSON J, BJORK L, ANDERSSON U: Lymphokine production induced by Streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 1994; 24: 916.